samedan logo
 
 
 
spacer
home > ebr > spring 2008 > twenty-first century recruits
PUBLICATIONS
European Biopharmaceutical Review

Twenty-First Century Recruits

Talent acquisition today poses numerous challenges and opportunities for the life sciences industry. Pete Leddy of Invitrogen explores the changing world of pharmaceutical recruitment

Recruiting and retaining top employees is critical in order to secure a company’s continued success. As the biotechnology industry grows and expands, its talent needs rapidly increase, while the pool of qualified, diverse applicants is shrinking. This article explores the overall environment for talent acquisition (TA) in the life sciences and discusses why a solid TA plan is essential to achieving business goals. It will focus on a few of the challenges and experiences faced by the industry over the next few years, and will outline the resources that companies have at their disposal to attract and retain top talent.

BUSINESS GOALS IN THE SHORT AND LONG TERM

In developing a talent acquisition plan, companies must examine both long- and short-term business goals in order to align any hiring with those goals. What must a company accomplish in order to grow? The answer to that question will evidently vary significantly from company to company. Biotechnology and pharmaceutical companies poised to enter the clinic must be adept at planning clinical trials and working with regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMEA). On the other hand, biotechnology tools companies seeking to offer ever more advanced technologies to life sciences researchers must continue to invest in newer technologies and build strong infrastructures to meet the demands of their customers.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Pete Leddy is Senior Vice President of Human Resources for Invitrogen, where he oversees global HR strategy and manages all aspects of the field. Prior to joining Invitrogen in 2005, Pete served as Vice President of Human Resources for the Americas operations of Dell Incorporated. He holds a PhD and a Master of Science degree in Industrial Organizational Psychology from the Illinois Institute of Technology.
spacer
Pete Leddy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch

Waiblingen/Germany, October 6, 2021. Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the "Partnership Innovation" category, the Parental Drug Association (PDA) honors development projects by pharmaceutical and machine manufacturers that advance the production of (bio)pharmaceuticals. The collaboration between Vetter and Syntegon resulted in Versynta microBatch, a highly flexible and fully automated production cell with a gloveless isolator, the smallest possible dimensions and a complete batch-to-batch changeover of less than two hours.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement